Skip to main content Skip to navigation
CD117 (104D2) BV605
Product Details
Down Arrow Up Arrow


BD®
KIT; c-Kit; SCFR; PBT; Mast/stem cell growth factor receptor
Human
Mouse BALB/c IgG1
Megakaryoctic cell line MOLM-1
Flow cytometry
5 µl
VI C30
3815
IVD


Preparation And Storage

The antibody reagent is stable until the expiration date shown on the label when stored at 2° to 8°C. Do not use after the expiration date. Do not freeze the reagent or expose it to direct light during storage or incubation with cells. Keep the outside of the reagent vial dry.Do not use the reagent if you observe any change in appearance. Precipitation or discoloration indicates instability or deterioration.

664452 Rev. 1
Antibody Details
Down Arrow Up Arrow
104D2
664452 Rev. 1
Format Details
Down Arrow Up Arrow
BV605
The BD Horizon Brilliant Violet™ 605 (BV605) dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 605-nm. BV605, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 610-nm (e.g., a 610/20-nm bandpass filter). The acceptor dye can be excited by the yellow-green (561-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV605
Violet 405 nm
407 nm
605 nm
664452 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (18)

  1. Advani AS, Tiu R, Saunthararajah Y, et al. A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia.. Leuk Res. 2010; 34(12):1622-6. View Reference
  2. Ashman LK, Cambareri A, Nguyen L, Bühring H-J. CD117 workshop panel report. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:816-818.
  3. Berardi AC, Wang A, Levine JD, Lopez P, Scadden DT. Functional isolation and characterization of human hematopoietic stem cells. Science. 1995; 267:104-108. View Reference
  4. Briddell RA, Broudy VC, Bruno E, Brandt JE, Srour EF, Hoffman R. Further phenotypic characterization and isolation of human hematopoietic progenitor cells using a monoclonal antibody to the c-kit receptor. Blood. 1992; 79:3159-3167. View Reference
  5. Broudy VC, Lin N, Zsebo KM, et al. Isolation and characterization of a monoclonal antibody that recognizes the human c-kit receptor. Blood. 1992; 79:338-346. View Reference
  6. Clinical and Laboratory Standards Institute. Collection of Diagnostic Venous Blood Specimens, 7th ed. In: CLSI. CLSI, ed. CLSI document GP41-A7. Wayne, PA: Clinical and Laboratory Standards Institute; 2017:1-85. View Reference
  7. Dunphy CH, Tang W. The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases.. Arch Pathol Lab Med. 2007; 131(5):748-54. View Reference
  8. Ehninger A, Kramer M, Röllig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.. Blood Cancer J. 2014; 4(6):e218. View Reference
  9. Gunji Y, Nakamura M, Osawa H, et al. Human primitive hematopoietic progenitor cells are more enriched in KITlow cells than in KIThigh cells. Blood. 1993; 3283-3289.
  10. Haycocks NG, Lawrence L, Cain JW, Zhao XF. Optimizing antibody panels for efficient and cost-effective flow cytometric diagnosis of acute leukemia.. Cytometry B Clin Cytom. 2011; 80(4):221-9. View Reference
  11. Ikuta K, Weissman IL. Evidence that hematopoietic stem cells express mouse c-kit but do not depend on steel factor for their generation. Proc Natl Acad Sci U S A. 1992; 89(4):1502-1506. View Reference
  12. Matsuo Y, Adachi T, Tsubota T, Imanishi J, Minowada J. Establishment and characterization of a novel megakaryoblastic cell line, MOLM-1, from a patient with chronic myelogenous leukemia. Hum Immunol. 1991; 4:261-264. View Reference
  13. Newell JO, Cessna MH, Greenwood J, Hartung L, Bahler DW. Importance of CD117 in the evaluation of acute leukemias by flow cytometry. Cytometry. 2003; 52B:40-43.
  14. Okada S, Nakauchi H, Nagayoshi K, Nishikawa S, Miura Y, Suda T. Enrichment and characterization of murine hematopoietic stem cells that express c-kit molecule. Blood. 1991; 78:1706-1712. View Reference
  15. Olweus J, Terstappen LW, Thompson PA, Lund-Johansen F. Expression and function of receptors for stem cell factor and erythropoietin during lineage commitment of human hematopoietic progenitor cells. Blood. 1996; 88:1594-1607. View Reference
  16. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis.. Leukemia. 1996; 10(5):877-95. View Reference
  17. Simmons PJ, Aylett GW, Niutta S, To LB, Juttner CA, Ashman LK. c-kit is expressed by primitive human hematopoietic cells that give rise to colony-forming cells in stroma-dependent or cytokine-supplemented culture. Exp Hematol. 1994; 22:157-165. View Reference
  18. Yarden Y, Kuang W-J, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidenti ed ligand. EMBO J. 1987; 6:3341-3351.
View All (18) View Less
664452 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For In Vitro Diagnostics Use.

Documents are subject to revision without notice. Please verify you have the correct revision of the document, and always refer back to BD's eIFU website for the latest and most up to date information.